Terapia con linfocitos T con Car vs quimioterapia en pacientes con leucemia linfoblática aguda
87 páginas : gráficas
- Autores:
-
González Garcés, Alexandra Pahola
Triana Niño, Andrea
- Tipo de recurso:
- Trabajo de grado de pregrado
- Fecha de publicación:
- 2019
- Institución:
- Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
- Repositorio:
- Repositorio Institucional UDCA
- Idioma:
- spa
- OAI Identifier:
- oai:repository.udca.edu.co:11158/2744
- Acceso en línea:
- https://repository.udca.edu.co/handle/11158/2744
- Palabra clave:
- Leucemia-Linfoma Linfoblástico de Células Precursoras
Linfocitos T
Qumioterapia
- Rights
- openAccess
- License
- Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales
| id |
RepoUDCA2_9e3e815c82ff66c10ab22f86d0fb1050 |
|---|---|
| oai_identifier_str |
oai:repository.udca.edu.co:11158/2744 |
| network_acronym_str |
RepoUDCA2 |
| network_name_str |
Repositorio Institucional UDCA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Terapia con linfocitos T con Car vs quimioterapia en pacientes con leucemia linfoblática aguda |
| title |
Terapia con linfocitos T con Car vs quimioterapia en pacientes con leucemia linfoblática aguda |
| spellingShingle |
Terapia con linfocitos T con Car vs quimioterapia en pacientes con leucemia linfoblática aguda Leucemia-Linfoma Linfoblástico de Células Precursoras Linfocitos T Qumioterapia |
| title_short |
Terapia con linfocitos T con Car vs quimioterapia en pacientes con leucemia linfoblática aguda |
| title_full |
Terapia con linfocitos T con Car vs quimioterapia en pacientes con leucemia linfoblática aguda |
| title_fullStr |
Terapia con linfocitos T con Car vs quimioterapia en pacientes con leucemia linfoblática aguda |
| title_full_unstemmed |
Terapia con linfocitos T con Car vs quimioterapia en pacientes con leucemia linfoblática aguda |
| title_sort |
Terapia con linfocitos T con Car vs quimioterapia en pacientes con leucemia linfoblática aguda |
| dc.creator.fl_str_mv |
González Garcés, Alexandra Pahola Triana Niño, Andrea |
| dc.contributor.advisor.spa.fl_str_mv |
Urrego Novoa, José Ricardo, dir. |
| dc.contributor.author.spa.fl_str_mv |
González Garcés, Alexandra Pahola Triana Niño, Andrea |
| dc.subject.mesh.spa.fl_str_mv |
Leucemia-Linfoma Linfoblástico de Células Precursoras Linfocitos T Qumioterapia |
| topic |
Leucemia-Linfoma Linfoblástico de Células Precursoras Linfocitos T Qumioterapia |
| description |
87 páginas : gráficas |
| publishDate |
2019 |
| dc.date.issued.spa.fl_str_mv |
2019 |
| dc.date.accessioned.spa.fl_str_mv |
2020-02-11T13:36:51Z |
| dc.date.available.spa.fl_str_mv |
2020-02-11T13:36:51Z |
| dc.type.spa.fl_str_mv |
Trabajo de grado - Pregrado |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/TP |
| format |
http://purl.org/coar/resource_type/c_7a1f |
| status_str |
publishedVersion |
| dc.identifier.uri.spa.fl_str_mv |
https://repository.udca.edu.co/handle/11158/2744 |
| dc.identifier.local.spa.fl_str_mv |
QF027 G65t 2019 (205830) |
| url |
https://repository.udca.edu.co/handle/11158/2744 |
| identifier_str_mv |
QF027 G65t 2019 (205830) |
| dc.language.iso.spa.fl_str_mv |
spa |
| language |
spa |
| dc.relation.references.spa.fl_str_mv |
Jiménez-Morales S, Hidalgo-Miranda A, Ramírez-Bello J. Acute lymphoblastic leukemia: a genomic perspective. Vol. 74, Boletin Medico del Hospital Infantil de Mexico. MassonDoyma Mexico, S.A.; 2017. p. 13–26. Moxon-Emre I, Bouffet E, Taylor MD, Laperriere N, Scantlebury N, Law N, et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. Journal of Clinical Oncology. 2014 Jun 10;32(17):1760–8. Centro Nacional de Investigación en evidencia y Tecnologías en Salud C. Guia Colombiana de Leucemia en Niños 2013. Guía Colombiana de Leucemia en niños, niñas y adolescentes. 2013 Apr;9. Observatory G production: GC. Cáncer hoy [Internet]. Cáncer hoy. 2018. Available from: http://gco.iarc.fr/today/online-analysispie?v=2018&mode=population&mode_population=countries&population=900&population s=900&key=total&sex=0&cancer=36&type=0&statistic=5&prevalence=0&population_gro up=2&ages_group%5B%5D=0&ages_group%5B%5D=2&nb_items=7&grou Observatory G production: GCG. Cáncer Hoy [Internet]. 2018. Available from: http://gco.iarc.fr/today/online-analysispie?v=2018&mode=population&mode_population=countries&population=900&population s=900&key=total&sex=0&cancer=36&type=0&statistic=5&prevalence=0&population_gro up=2&ages_group%5B%5D=0&ages_group%5B%5D=2&nb_items=7&grou Global GPGCO. Tasa de incidenciay mortalidad estandarizadas por edad (Mundial) en 2018, América Latina, y el Caribe, Colombia, ambos sexos, edades 0-14 [Internet]. 2018. Available from: http://gco.iarc.fr/today/online-analysis-multibars?v=2018&mode=cancer&mode_population=countries&population=900&populations= 904_170&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_gro up=0&ages_group%5B%5D=0&ages_group%5B%5D=2&nb_items=1 Castillo-Martínez ID, Juárez-Villegas LE, Palomo-Colli MÁ, Medina-Sansón A, Zapata-Tarrés M. Calidad de vida en niños con leucemia linfoblástica aguda durante la inducción a la remisión mediante el PedsQL Cancer Module©. Boletín médico del Hospital Infantil de México [Internet]. 2009;66:410–8. Available from: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1665- 11462009000500003&nrm=iso Jiménez C, Ángel M, Vargas O, Carlos L, Arenas R, Mattos S. Artículos de Revisión Epidemiología de la leucemia. 2007; Labardini Méndez JR, Ceballos EC, Genaro O, Navarro L, Alfaro CC, Balbuena Martínez M, et al. Leucemia Linfoblástica Aguda. 2011. All LL, Domínguez I, I CMA, I SMG, María R, I LD, et al. Correlación entre morfología y citometría de flujo en la Leucemia Linfoide Aguda Infantil Correlation between morphology and flow cytometry in A cute. Revista Cubana de Hematología, Inmunol y Hemoter [Internet]. 2016;32(4):483–93. Available from: http://www.medigraphic.com/pdfs/revcubheminmhem/rch-2016/rch164g.pdf Farias MG, Castro SM de. Diagnøstico laboratorial das leucemias linfóides agudas. J Bras Patol Med Lab. 2004;40(2):91–8. Miale J. books. Hematología: Medicina de laboratorio [Internet]. 1985; Available from: https://books.google.com.co/books?id=AyG5MzGyuo4C&pg=PA812&dq=Leucemia+linfob lástica+Aguda&hl=es&sa=X&ved=0ahUKEwjx14qj9rrlAhWlp1kKHbkCDTAQ6AEILjAB#v=one page&q=Leucemia linfoblástica Aguda&f=false Rodak B, Fristma G, Elaine K. Hematología: Fundamentos y aplicaciones clínicas. In: Hematología: Fundamentos y aplicaciones clínicas [Internet]. 2°. Montevideo, Uruguay: Editorial médica Panaméricana; 2002. Available from: https://books.google.com.co/books?id=rFqhpbKnWX8C&pg=PA317&dq=Fundamentos+d e+hematología+cuarta+edición&hl=es&sa=X&ved=0ahUKEwiCpoXOvZ_lAhXSuFkKHX87CcQ6AEILzAB#v=onepage&q=Fundamentos de hematología cuarta edición&f=false Ruiz G. Capitulo 12: Leucemias agudas. In: Panaméricana EM, editor. Fundamentos de Hematología [Internet]. 4°. Argentina: Editorial Médica Panaméricana; 2009. p. 143. Available from: https://books.google.com.co/books?id=6ptpJtl80UwC&pg=PR11&dq=Fundamentos+de+hematología+cuarta+edición&hl=es&sa=X&ved=0ahUKEwiCpoXOvZ_lAhXSuFkKHX87CcQ6AEIKDAA#v=onepage&q=leucemia&f=false Madrigal G. Leucemia Linfoblástica aguda. In: Rica E de la U de C, editor. Manual de diagnóstico y Terapéutica en pediatría [Internet]. 1° Edición. Costa Rica; 2003. p. 288. Available from: https://books.google.com.co/books?id=fTx1FsC5oI0C&pg=PA288&dq=Leucemia+linfoblá stica+Aguda+epidemiología&hl=es&sa=X&ved=0ahUKEwimmuCO9LrlAhVCjlkKHcagChcQ6 AEIKDAA#v=onepage&q=Leucemia linfoblástica Aguda epidemiología&f=false Cancer. SA de. Signos y síntomas de la leucemia linfocíticas agudas. [Internet]. Detección temprana, diagnóstico y tipos. 2018. Available from: https://www.cancer.org/es/cancer/leucemia-linfocitica-aguda/deteccion-diagnosticoclasificacion-por-etapas/senales-sintomas.html Cancer. SA de. Cancer [Internet]. Pruebas para la leucemia linfocítica aguda. 2018. Available from: https://www.cancer.org/es/cancer/leucemia-linfociticaaguda/deteccion-diagnostico-clasificacion-por-etapas/como-se-diagnostica.html UU, Cancer de los institutos de salud de los EE IN de. Para LLA infantil, se utiliza grupos de riesgo en lugar de estadios para planificar el tratamiento. [Internet]. Tratamiento de Leucemia linfoblástica aguda infantil (PQD). 2019. Available from: https://www.cancer.gov/espanol/tipos/leucemia/paciente/tratamiento-lla-infantilpdq#_1 Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82,85,89,92 and 97. Leukemia [Internet]. 2010;24(2):298–308. Available from: http://dx.doi.org/10.1038/leu.2009.249 Cáncer IN del. Tratamiento de la leucemia linfoblástica aguda infantil (PDQ)-Versión para pacientes. [Internet]. Tipos de cáncer. 2019. Available from: https://www.cancer.gov/espanol/tipos/leucemia/paciente/tratamiento-lla-infantilpdq goleman, daniel; boyatzis, Richard; Mckee A. 済無Ficha técnica prednisolona. Journal of Chemical Information and Modeling. 2019;53(9):1689–99. Medicamento NDEL, Cuantitativa CCY. Ficha Técnica Vincristina. Medicamentos. FN de. Vincristina [Internet]. Vincristina. 2012. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=234 Medicamento NDEL. Daunorrubicina. :1–16. Available from: http://cima.aemps.es/cima/pdfs/es/ft/46427/46427_ft.pdf Médicas. CN de información de C. L-Asparaginasa [Internet]. L-asparaginasa. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=258 García CG. Farmacología del metotrexato. 2016;11(1):3–7. Medicamento NDEL. Ficha técnica Ciclofosfamida. [Internet]. Available from: https://cima.aemps.es/cima/pdfs/es/ft/79067/FichaTecnica_79067.html.pdf Ministerio de sanidad política social e igualdad. Ficha técnica Mesna [Internet]. Available from: https://cima.aemps.es/cima/pdfs/es/ft/79067/FichaTecnica_79067.html.pdf Gennaro A. Citarabina. In: Panamericana E médica, editor. Remington Farmacia [Internet]. 20° edició. Montevideo, Uruguay; 2000. p. 1770. Available from: https://books.google.com.co/books?id=5SGJ4ezraG4C&pg=PA1793&dq=Mesna+mecanis mo+de+acción&hl=es&sa=X&ved=0ahUKEwj8ltD_s7jlAhVmqlkKHfPZDdkQ6AEISDAE#v=one page&q=citarabina&f=false Médicos. CN de información de C. 6-Mercaptopurina. [Internet]. Formulario Nacional De Información de Ciencias Médicas. 2010. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=70 Médicos. CN de información de C. Dexametasona [Internet]. Dexametasona. 2012. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=70 Folinato Cálcico. [Internet]. p. 1–9. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=70 Del I, Autores FY, Informe DEL. Hospital de Cabueñes Servicio de Farmacia Centro de Información de Medicamentos. Pegfilgrastim. 2008;1–10. Martínez-Sánchez LM, Álvarez-Hernández LF, Roldán-Isaza M. Car T cells: Progress that passes the advances in the treatment of malignant hemopathies. Revista Cubana de Hematologia, Inmunologia y Hemoterapia. 2018;34(4):41–50. Sanidad DE, Social YB. GRAVES EN PACIENTES TRATADOS CON MEDICAMENTOS QUE CONTIENEN CÉLULAS T CAR ( CHIMERIC ANTIGEN RECEPTOR ) Desarrollado por el grupo de expertos en la utilización de medicamentos CAR del “ Plan de abordaje de las terapias avanzadas en el SNS : medicamentos C. 2019;1–16. Sanabria AJ, Rigau D, Rotaeche R, Selva A, Marzo-Castillejo M, Alonso-Coello P. Sistema GRADE: Metodología para la realización de recomendaciones para la práctica clínica. Atencion Primaria [Internet]. 2015;47(1):48–55. Available from: http://dx.doi.org/10.1016/j.aprim.2013.12.013 Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine. 2018 Feb 1;378(5):439–48. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine. 2018 Feb 1;378(5):439–48. Cheng Z, Wei R, Ma Q, Shi L, He F, Shi Z, et al. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. Molecular Therapy. 2018 Apr 4;26(4):976–85. Valecha GK, Ibrahim U, Ghanem S, Asti D, Atallah JP, Terjanian T. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Vol. 10, Expert Review of Hematology. Taylor and Francis Ltd; 2017. p. 783–99. Forsberg MH, Das A, Saha K, Capitini CM. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Vol. 14, Therapeutics and Clinical Risk Management. Dove Medical Press Ltd.; 2018. p. 1573–84. Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017 Dec 1;31(12):2587–93. Beatty GL, O’Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology [Internet]. 2018;155(1):29–32. Available from: https://doi.org/10.1053/j.gastro.2018.03.029 Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New England Journal of Medicine. 2018;378(5):449–59. Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, et al. Study protocol for THINK: A multinational open-label phase i study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 2017;7(11) Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst J, et al. HHS Public Access. 2018;5(12):1152–61. Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-Specific chimeric antigen Receptor-modified T cells after failure of ibrutinib. Journal of Clinical Oncology. 2017;35(26):3010–20. Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunology, Immunotherapy. 2017;66(11):1425–36. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. Journal for ImmunoTherapy of Cancer. 2017;5(1):1–14. Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Mehta B, et al. HHS Public Access. 2018;23(14):3499–509. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy [Internet]. 2017;25(1):285–95. Available from: http://dx.doi.org/10.1016/j.ymthe.2016.10.020 Cai B, Guo M, Wang Y, Zhang Y, Yang J, Guo Y, et al. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. Journal of Hematology and Oncology [Internet]. 2016;9(1):1–6. Available from: http://dx.doi.org/10.1186/s13045-016-0357-z Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine. 2016;8(355). Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: An open-label phase i trial. Clinical Cancer Research. 2017;23(5):1156–66. Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-Bcell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688–700. Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, et al. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected from Activation-induced Cell Death by PD-1 Blockade. Molecular Therapy. 2016;24(6):1135–49. Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117–27. Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptormodified T-cell therapy for CEA+ liver metastases. Clinical Cancer Research. 2015;21(14):3149–59 Stainken F, Assanah EO, Khare PD, Davies R, Espat NJ. Neutrophil: Lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor modified T cell infusions for liver metastases. 2015;21(11):457–62. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Maryalice SS, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology. 2015;33(6):540–9. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. American Journal of Hematology. 2019;94(S1):S3–9. Lu YJ, Chu H, Wheeler LW, Nelson M, Westrick E, Matthaei JF, et al. Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric malignancies. Frontiers in Oncology. 2019;9(MAR). Wen S, Niu Z, Xing L, Wang Y, Li H, Kuang N, et al. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: A case report. BMC Cancer. 2018;18(1):1–7. Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine. 2018 Oct 1;24(10):1499–503. Manuscript A. NIH Public Access. 2014;27(4):1–19 Gruntman AM, Flotte TR. The rapidly evolving state of gene therapy. FASEB Journal. 2018;32(4):1733–40. Tasian SK. Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? Therapeutic Advances in Hematology. 2018;9(6):135–48. Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T cell (CART) immunotherapy for solid tumors: Lessons learned and strategies for moving forward. Journal of Hematology and Oncology. 2018;11(1). Perica K, Curran KJ, Brentjens RJ, Giralt SA, Sloan M, Cancer K, et al. HHS Public Access. 2019;24(6):1135–41. American Society of clinical Oncology (ASCO). [Internet]. Quimioterapia LLA. Available from:https://www.cancer.net/es/tipos-de-c%C3%A1ncer/leucemialinfobl%C3%A1stica-aguda-all-infantil/opciones-de-tratamiento |
| dc.rights.spa.fl_str_mv |
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) |
| rights_invalid_str_mv |
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales https://creativecommons.org/licenses/by-nc-sa/4.0/ Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019 |
| dc.publisher.faculty.spa.fl_str_mv |
Facultad de Ciencias |
| dc.publisher.program.spa.fl_str_mv |
Química Farmacéutica |
| institution |
Universidad de Ciencias Aplicadas y Ambientales U.D.C.A |
| bitstream.url.fl_str_mv |
https://repository.udca.edu.co/bitstreams/9abceed3-dadd-444e-a326-31bde844f762/download https://repository.udca.edu.co/bitstreams/4d880d58-b327-4bcf-8511-a8e2a9590260/download https://repository.udca.edu.co/bitstreams/ed28dcf2-7c8d-4711-8b50-f1fb5851eee2/download https://repository.udca.edu.co/bitstreams/54a30d7b-3f71-4eda-beb9-ef7eeb8a45b7/download |
| bitstream.checksum.fl_str_mv |
c7ea1abde895a0e746401e66e28e018e f661acf14bedbf9f5d13897a0387e751 b60b72e109dd58d3698da14824440428 841ec7297d346d6e204b0447f5e9c17d |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA. |
| repository.mail.fl_str_mv |
bdigital@metabiblioteca.com |
| _version_ |
1814213219009429504 |
| spelling |
Urrego Novoa, José Ricardo, dir.González Garcés, Alexandra PaholaTriana Niño, Andrea2020-02-11T13:36:51Z2020-02-11T13:36:51Z2019https://repository.udca.edu.co/handle/11158/2744QF027 G65t 2019 (205830)87 páginas : gráficasAbstract: A comparison was made between two therapies for the treatment of lymphoblastic water leukemia in a pediatric population from 2 to 10 compared therapies were the chemotherapy scheme for high, intermediate or standard risk of precursors B and T Vs CAR-T immunological therapy, variables such as effectiveness, efficacy and / or safety profile were evaluated. It was found that these therapies are currently complementary, in order for CAR-T therapy to be more effective, the patient must be pre-conditioned with a chemotherapy scheme or with drugs of this scheme that are immunosuppressive, it was also possible to show that the dose of cells administered CAR-T is essential to avoid serious adverse effects in the patient such as cytokine release syndrome. Methods: A qualitative systematic review was conducted and guided by the protocol of said systematic review approximately 55 articles were evaluated where information on these therapies was collected. Results: Through the prism diagram and search equations, a total of 14 articles were obtained which, when evaluated with the GRADE Scale, identified that there are no studies comparing the chemotherapy scheme and CAR-T, in some of the studies These therapies are complementary, since in order to achieve optimal effectiveness of CAR-T, a pre-conditioning is performed on the patient with a chemotherapy scheme or with some drugs of that scheme that are immunosuppressive. Conclusions: It was found that both therapies can make the patient reach a state of complete remission, just as in both therapies one can relapse after a while even after having achieved a remission.En el presente artículo se describe una comparación entre dos terapias para el tratamiento de la leucemia linfoblastica agua en población pediátrica de 2 a a10 las terapias comparadas fueron el esquema de quimioterapia para riesgo alto, intermedio o estándar de precursores B y T Vs la terapia inmunológica CAR-T, se evaluaron variables como efectividad, eficacia y/o perfil de seguridad. Se encontró que actualmente estas terapias son complementarias, para que la terapia CAR-T tenga mayor eficacia se debe pre acondicionar al paciente con un esquema de quimioterapia o con medicamentos de este esquema que sean inmunosupresores, también se logró evidenciar que la dosis de células administradas de CAR-T es fundamental para evitar efectos adversos graves en el paciente como de síndrome de liberación de citoquinas. Métodos: Se realizo una revisión sistemática cualitativa y guiados bajo el protocolo de dicha revisión sistemática se evaluaron aproximadamente 55 artículos donde se recopilo información de estas terapias. Resultados: Por medio del diagrama prisma y ecuaciones de búsqueda se obtuvieron un total de 14 artículos los cuales al ser evaluados con la Escala GRADE se identifico que no hay estudios que comparen el esquema de quimioterapia y la CAR-T, en algunos de los estudios estos estas terapias son complementarias, ya que para logra una efectividad optima de la CAR-T se realiza un pre acondicionamiento al paciente con un esquema de quimioterapia o con algunos medicamentos de dicho esquema que sean inmunosupresores. Conclusiones: Se encontró que ambas terapias pueden hacer que el paciente llegue a estado de remisión completa, al igual que en ambas terapias se puede tener recaída después de un tiempo incluso después de haber logrado una remisión.Incluye bibliografíaPregradoQuímico(a) Farmacéuticoapplication/pdfspaBogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica FarmacéuticaDerechos Reservados - Universidad de Ciencias Aplicadas y Ambientaleshttps://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccessAtribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)http://purl.org/coar/access_right/c_abf2Leucemia-Linfoma Linfoblástico de Células PrecursorasLinfocitos TQumioterapiaTerapia con linfocitos T con Car vs quimioterapia en pacientes con leucemia linfoblática agudaTrabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/redcol/resource_type/TPhttp://purl.org/coar/version/c_970fb48d4fbd8a85Jiménez-Morales S, Hidalgo-Miranda A, Ramírez-Bello J. Acute lymphoblastic leukemia: a genomic perspective. Vol. 74, Boletin Medico del Hospital Infantil de Mexico. MassonDoyma Mexico, S.A.; 2017. p. 13–26.Moxon-Emre I, Bouffet E, Taylor MD, Laperriere N, Scantlebury N, Law N, et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. Journal of Clinical Oncology. 2014 Jun 10;32(17):1760–8.Centro Nacional de Investigación en evidencia y Tecnologías en Salud C. Guia Colombiana de Leucemia en Niños 2013. Guía Colombiana de Leucemia en niños, niñas y adolescentes. 2013 Apr;9.Observatory G production: GC. Cáncer hoy [Internet]. Cáncer hoy. 2018. Available from: http://gco.iarc.fr/today/online-analysispie?v=2018&mode=population&mode_population=countries&population=900&population s=900&key=total&sex=0&cancer=36&type=0&statistic=5&prevalence=0&population_gro up=2&ages_group%5B%5D=0&ages_group%5B%5D=2&nb_items=7&grouObservatory G production: GCG. Cáncer Hoy [Internet]. 2018. Available from: http://gco.iarc.fr/today/online-analysispie?v=2018&mode=population&mode_population=countries&population=900&population s=900&key=total&sex=0&cancer=36&type=0&statistic=5&prevalence=0&population_gro up=2&ages_group%5B%5D=0&ages_group%5B%5D=2&nb_items=7&grouGlobal GPGCO. Tasa de incidenciay mortalidad estandarizadas por edad (Mundial) en 2018, América Latina, y el Caribe, Colombia, ambos sexos, edades 0-14 [Internet]. 2018. Available from: http://gco.iarc.fr/today/online-analysis-multibars?v=2018&mode=cancer&mode_population=countries&population=900&populations= 904_170&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_gro up=0&ages_group%5B%5D=0&ages_group%5B%5D=2&nb_items=1Castillo-Martínez ID, Juárez-Villegas LE, Palomo-Colli MÁ, Medina-Sansón A, Zapata-Tarrés M. Calidad de vida en niños con leucemia linfoblástica aguda durante la inducción a la remisión mediante el PedsQL Cancer Module©. Boletín médico del Hospital Infantil de México [Internet]. 2009;66:410–8. Available from: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1665- 11462009000500003&nrm=isoJiménez C, Ángel M, Vargas O, Carlos L, Arenas R, Mattos S. Artículos de Revisión Epidemiología de la leucemia. 2007;Labardini Méndez JR, Ceballos EC, Genaro O, Navarro L, Alfaro CC, Balbuena Martínez M, et al. Leucemia Linfoblástica Aguda. 2011.All LL, Domínguez I, I CMA, I SMG, María R, I LD, et al. Correlación entre morfología y citometría de flujo en la Leucemia Linfoide Aguda Infantil Correlation between morphology and flow cytometry in A cute. Revista Cubana de Hematología, Inmunol y Hemoter [Internet]. 2016;32(4):483–93. Available from: http://www.medigraphic.com/pdfs/revcubheminmhem/rch-2016/rch164g.pdfFarias MG, Castro SM de. Diagnøstico laboratorial das leucemias linfóides agudas. J Bras Patol Med Lab. 2004;40(2):91–8.Miale J. books. Hematología: Medicina de laboratorio [Internet]. 1985; Available from: https://books.google.com.co/books?id=AyG5MzGyuo4C&pg=PA812&dq=Leucemia+linfob lástica+Aguda&hl=es&sa=X&ved=0ahUKEwjx14qj9rrlAhWlp1kKHbkCDTAQ6AEILjAB#v=one page&q=Leucemia linfoblástica Aguda&f=falseRodak B, Fristma G, Elaine K. Hematología: Fundamentos y aplicaciones clínicas. In: Hematología: Fundamentos y aplicaciones clínicas [Internet]. 2°. Montevideo, Uruguay: Editorial médica Panaméricana; 2002. Available from: https://books.google.com.co/books?id=rFqhpbKnWX8C&pg=PA317&dq=Fundamentos+d e+hematología+cuarta+edición&hl=es&sa=X&ved=0ahUKEwiCpoXOvZ_lAhXSuFkKHX87CcQ6AEILzAB#v=onepage&q=Fundamentos de hematología cuarta edición&f=falseRuiz G. Capitulo 12: Leucemias agudas. In: Panaméricana EM, editor. Fundamentos de Hematología [Internet]. 4°. Argentina: Editorial Médica Panaméricana; 2009. p. 143. Available from: https://books.google.com.co/books?id=6ptpJtl80UwC&pg=PR11&dq=Fundamentos+de+hematología+cuarta+edición&hl=es&sa=X&ved=0ahUKEwiCpoXOvZ_lAhXSuFkKHX87CcQ6AEIKDAA#v=onepage&q=leucemia&f=falseMadrigal G. Leucemia Linfoblástica aguda. In: Rica E de la U de C, editor. Manual de diagnóstico y Terapéutica en pediatría [Internet]. 1° Edición. Costa Rica; 2003. p. 288. Available from: https://books.google.com.co/books?id=fTx1FsC5oI0C&pg=PA288&dq=Leucemia+linfoblá stica+Aguda+epidemiología&hl=es&sa=X&ved=0ahUKEwimmuCO9LrlAhVCjlkKHcagChcQ6 AEIKDAA#v=onepage&q=Leucemia linfoblástica Aguda epidemiología&f=falseCancer. SA de. Signos y síntomas de la leucemia linfocíticas agudas. [Internet]. Detección temprana, diagnóstico y tipos. 2018. Available from: https://www.cancer.org/es/cancer/leucemia-linfocitica-aguda/deteccion-diagnosticoclasificacion-por-etapas/senales-sintomas.htmlCancer. SA de. Cancer [Internet]. Pruebas para la leucemia linfocítica aguda. 2018. Available from: https://www.cancer.org/es/cancer/leucemia-linfociticaaguda/deteccion-diagnostico-clasificacion-por-etapas/como-se-diagnostica.htmlUU, Cancer de los institutos de salud de los EE IN de. Para LLA infantil, se utiliza grupos de riesgo en lugar de estadios para planificar el tratamiento. [Internet]. Tratamiento de Leucemia linfoblástica aguda infantil (PQD). 2019. Available from: https://www.cancer.gov/espanol/tipos/leucemia/paciente/tratamiento-lla-infantilpdq#_1Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82,85,89,92 and 97. Leukemia [Internet]. 2010;24(2):298–308. Available from: http://dx.doi.org/10.1038/leu.2009.249Cáncer IN del. Tratamiento de la leucemia linfoblástica aguda infantil (PDQ)-Versión para pacientes. [Internet]. Tipos de cáncer. 2019. Available from: https://www.cancer.gov/espanol/tipos/leucemia/paciente/tratamiento-lla-infantilpdqgoleman, daniel; boyatzis, Richard; Mckee A. 済無Ficha técnica prednisolona. Journal of Chemical Information and Modeling. 2019;53(9):1689–99.Medicamento NDEL, Cuantitativa CCY. Ficha Técnica Vincristina.Medicamentos. FN de. Vincristina [Internet]. Vincristina. 2012. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=234Medicamento NDEL. Daunorrubicina. :1–16. Available from: http://cima.aemps.es/cima/pdfs/es/ft/46427/46427_ft.pdfMédicas. CN de información de C. L-Asparaginasa [Internet]. L-asparaginasa. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=258García CG. Farmacología del metotrexato. 2016;11(1):3–7.Medicamento NDEL. Ficha técnica Ciclofosfamida. [Internet]. Available from: https://cima.aemps.es/cima/pdfs/es/ft/79067/FichaTecnica_79067.html.pdfMinisterio de sanidad política social e igualdad. Ficha técnica Mesna [Internet]. Available from: https://cima.aemps.es/cima/pdfs/es/ft/79067/FichaTecnica_79067.html.pdfGennaro A. Citarabina. In: Panamericana E médica, editor. Remington Farmacia [Internet]. 20° edició. Montevideo, Uruguay; 2000. p. 1770. Available from: https://books.google.com.co/books?id=5SGJ4ezraG4C&pg=PA1793&dq=Mesna+mecanis mo+de+acción&hl=es&sa=X&ved=0ahUKEwj8ltD_s7jlAhVmqlkKHfPZDdkQ6AEISDAE#v=one page&q=citarabina&f=falseMédicos. CN de información de C. 6-Mercaptopurina. [Internet]. Formulario Nacional De Información de Ciencias Médicas. 2010. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=70Médicos. CN de información de C. Dexametasona [Internet]. Dexametasona. 2012. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=70Folinato Cálcico. [Internet]. p. 1–9. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=70Del I, Autores FY, Informe DEL. Hospital de Cabueñes Servicio de Farmacia Centro de Información de Medicamentos. Pegfilgrastim. 2008;1–10.Martínez-Sánchez LM, Álvarez-Hernández LF, Roldán-Isaza M. Car T cells: Progress that passes the advances in the treatment of malignant hemopathies. Revista Cubana de Hematologia, Inmunologia y Hemoterapia. 2018;34(4):41–50.Sanidad DE, Social YB. GRAVES EN PACIENTES TRATADOS CON MEDICAMENTOS QUE CONTIENEN CÉLULAS T CAR ( CHIMERIC ANTIGEN RECEPTOR ) Desarrollado por el grupo de expertos en la utilización de medicamentos CAR del “ Plan de abordaje de las terapias avanzadas en el SNS : medicamentos C. 2019;1–16.Sanabria AJ, Rigau D, Rotaeche R, Selva A, Marzo-Castillejo M, Alonso-Coello P. Sistema GRADE: Metodología para la realización de recomendaciones para la práctica clínica. Atencion Primaria [Internet]. 2015;47(1):48–55. Available from: http://dx.doi.org/10.1016/j.aprim.2013.12.013Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine. 2018 Feb 1;378(5):439–48.Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine. 2018 Feb 1;378(5):439–48.Cheng Z, Wei R, Ma Q, Shi L, He F, Shi Z, et al. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. Molecular Therapy. 2018 Apr 4;26(4):976–85.Valecha GK, Ibrahim U, Ghanem S, Asti D, Atallah JP, Terjanian T. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Vol. 10, Expert Review of Hematology. Taylor and Francis Ltd; 2017. p. 783–99.Forsberg MH, Das A, Saha K, Capitini CM. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Vol. 14, Therapeutics and Clinical Risk Management. Dove Medical Press Ltd.; 2018. p. 1573–84.Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017 Dec 1;31(12):2587–93.Beatty GL, O’Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology [Internet]. 2018;155(1):29–32. Available from: https://doi.org/10.1053/j.gastro.2018.03.029Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New England Journal of Medicine. 2018;378(5):449–59.Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, et al. Study protocol for THINK: A multinational open-label phase i study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 2017;7(11)Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst J, et al. HHS Public Access. 2018;5(12):1152–61.Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-Specific chimeric antigen Receptor-modified T cells after failure of ibrutinib. Journal of Clinical Oncology. 2017;35(26):3010–20.Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunology, Immunotherapy. 2017;66(11):1425–36.Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. Journal for ImmunoTherapy of Cancer. 2017;5(1):1–14.Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Mehta B, et al. HHS Public Access. 2018;23(14):3499–509.Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy [Internet]. 2017;25(1):285–95. Available from: http://dx.doi.org/10.1016/j.ymthe.2016.10.020Cai B, Guo M, Wang Y, Zhang Y, Yang J, Guo Y, et al. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. Journal of Hematology and Oncology [Internet]. 2016;9(1):1–6. Available from: http://dx.doi.org/10.1186/s13045-016-0357-zTurtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine. 2016;8(355).Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: An open-label phase i trial. Clinical Cancer Research. 2017;23(5):1156–66.Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-Bcell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688–700.Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, et al. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected from Activation-induced Cell Death by PD-1 Blockade. Molecular Therapy. 2016;24(6):1135–49.Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117–27.Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptormodified T-cell therapy for CEA+ liver metastases. Clinical Cancer Research. 2015;21(14):3149–59Stainken F, Assanah EO, Khare PD, Davies R, Espat NJ. Neutrophil: Lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor modified T cell infusions for liver metastases. 2015;21(11):457–62.Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Maryalice SS, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology. 2015;33(6):540–9.Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. American Journal of Hematology. 2019;94(S1):S3–9.Lu YJ, Chu H, Wheeler LW, Nelson M, Westrick E, Matthaei JF, et al. Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric malignancies. Frontiers in Oncology. 2019;9(MAR).Wen S, Niu Z, Xing L, Wang Y, Li H, Kuang N, et al. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: A case report. BMC Cancer. 2018;18(1):1–7.Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine. 2018 Oct 1;24(10):1499–503.Manuscript A. NIH Public Access. 2014;27(4):1–19Gruntman AM, Flotte TR. The rapidly evolving state of gene therapy. FASEB Journal. 2018;32(4):1733–40.Tasian SK. Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? Therapeutic Advances in Hematology. 2018;9(6):135–48.Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T cell (CART) immunotherapy for solid tumors: Lessons learned and strategies for moving forward. Journal of Hematology and Oncology. 2018;11(1).Perica K, Curran KJ, Brentjens RJ, Giralt SA, Sloan M, Cancer K, et al. HHS Public Access. 2019;24(6):1135–41.American Society of clinical Oncology (ASCO). [Internet]. Quimioterapia LLA. Available from:https://www.cancer.net/es/tipos-de-c%C3%A1ncer/leucemialinfobl%C3%A1stica-aguda-all-infantil/opciones-de-tratamientoPublicationORIGINALTerapia con linfocitos T con CAR Vs Quimioterapia para pacientes con LLA.pdfTerapia con linfocitos T con CAR Vs Quimioterapia para pacientes con LLA.pdfapplication/pdf1727183https://repository.udca.edu.co/bitstreams/9abceed3-dadd-444e-a326-31bde844f762/downloadc7ea1abde895a0e746401e66e28e018eMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-814775https://repository.udca.edu.co/bitstreams/4d880d58-b327-4bcf-8511-a8e2a9590260/downloadf661acf14bedbf9f5d13897a0387e751MD52TEXTTerapia con linfocitos T con CAR Vs Quimioterapia para pacientes con LLA.pdf.txtTerapia con linfocitos T con CAR Vs Quimioterapia para pacientes con LLA.pdf.txtExtracted texttext/plain138626https://repository.udca.edu.co/bitstreams/ed28dcf2-7c8d-4711-8b50-f1fb5851eee2/downloadb60b72e109dd58d3698da14824440428MD53THUMBNAILTerapia con linfocitos T con CAR Vs Quimioterapia para pacientes con LLA.pdf.jpgTerapia con linfocitos T con CAR Vs Quimioterapia para pacientes con LLA.pdf.jpgGenerated Thumbnailimage/jpeg3757https://repository.udca.edu.co/bitstreams/54a30d7b-3f71-4eda-beb9-ef7eeb8a45b7/download841ec7297d346d6e204b0447f5e9c17dMD5411158/2744oai:repository.udca.edu.co:11158/27442024-05-09 14:22:23.61https://creativecommons.org/licenses/by-nc-sa/4.0/Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientalesopen.accesshttps://repository.udca.edu.coRepositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA.bdigital@metabiblioteca.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 |